Pacer Advisors Inc. Sells 219,888 Shares of DENTSPLY SIRONA Inc. $XRAY

Pacer Advisors Inc. trimmed its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 90.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,973 shares of the medical instruments supplier’s stock after selling 219,888 shares during the quarter. Pacer Advisors Inc.’s holdings in DENTSPLY SIRONA were worth $266,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Southpoint Capital Advisors LP acquired a new position in shares of DENTSPLY SIRONA in the 1st quarter worth approximately $116,000,000. AQR Capital Management LLC boosted its stake in DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares in the last quarter. Armistice Capital LLC grew its position in DENTSPLY SIRONA by 1,044.0% in the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after acquiring an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. grew its position in DENTSPLY SIRONA by 662.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after acquiring an additional 4,003,606 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Brian P. Mckeon purchased 10,000 shares of the stock in a transaction dated Friday, June 12th. The stock was bought at an average cost of $10.12 per share, with a total value of $101,200.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at $101,200. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael J. Barber acquired 15,175 shares of DENTSPLY SIRONA stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the purchase, the director directly owned 55,943 shares in the company, valued at $552,716.84. The trade was a 37.22% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 35,160 shares of company stock valued at $351,179 in the last ninety days. 0.46% of the stock is owned by insiders.

Wall Street Analyst Weigh In

XRAY has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research note on Monday, August 3rd. BMO Capital Markets reiterated a “market perform” rating and set a $13.00 target price on shares of DENTSPLY SIRONA in a research report on Friday. Citigroup assumed coverage on shares of DENTSPLY SIRONA in a report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target for the company. UBS Group decreased their price objective on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, Piper Sandler lifted their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, DENTSPLY SIRONA presently has an average rating of “Hold” and a consensus price target of $13.38.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY opened at $11.61 on Wednesday. The stock has a market capitalization of $2.31 billion, a P/E ratio of -4.22, a P/E/G ratio of 1.42 and a beta of 0.85. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA Inc. has a 1-year low of $9.40 and a 1-year high of $14.86. The business has a 50-day moving average price of $11.84 and a two-hundred day moving average price of $11.88.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.35 by $0.17. The company had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. DENTSPLY SIRONA’s revenue was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts predict that DENTSPLY SIRONA Inc. will post 1.46 earnings per share for the current year.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.